321 related articles for article (PubMed ID: 31085178)
1. Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas.
Krug B; De Jay N; Harutyunyan AS; Deshmukh S; Marchione DM; Guilhamon P; Bertrand KC; Mikael LG; McConechy MK; Chen CCL; Khazaei S; Koncar RF; Agnihotri S; Faury D; Ellezam B; Weil AG; Ursini-Siegel J; De Carvalho DD; Dirks PB; Lewis PW; Salomoni P; Lupien M; Arrowsmith C; Lasko PF; Garcia BA; Kleinman CL; Jabado N; Mack SC
Cancer Cell; 2019 May; 35(5):782-797.e8. PubMed ID: 31085178
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.
Piunti A; Hashizume R; Morgan MA; Bartom ET; Horbinski CM; Marshall SA; Rendleman EJ; Ma Q; Takahashi YH; Woodfin AR; Misharin AV; Abshiru NA; Lulla RR; Saratsis AM; Kelleher NL; James CD; Shilatifard A
Nat Med; 2017 Apr; 23(4):493-500. PubMed ID: 28263307
[TBL] [Abstract][Full Text] [Related]
3. H3K27M in Gliomas Causes a One-Step Decrease in H3K27 Methylation and Reduced Spreading within the Constraints of H3K36 Methylation.
Harutyunyan AS; Chen H; Lu T; Horth C; Nikbakht H; Krug B; Russo C; Bareke E; Marchione DM; Coradin M; Garcia BA; Jabado N; Majewski J
Cell Rep; 2020 Nov; 33(7):108390. PubMed ID: 33207202
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous disruption of PRC2 and enhancer function underlies histone H3.3-K27M oncogenic activity in human hindbrain neural stem cells.
Brien GL; Bressan RB; Monger C; Gannon D; Lagan E; Doherty AM; Healy E; Neikes H; Fitzpatrick DJ; Deevy O; Grant V; Marqués-Torrejón MA; Alfazema N; Pollard SM; Bracken AP
Nat Genet; 2021 Aug; 53(8):1221-1232. PubMed ID: 34294917
[TBL] [Abstract][Full Text] [Related]
5. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.
Anastas JN; Zee BM; Kalin JH; Kim M; Guo R; Alexandrescu S; Blanco MA; Giera S; Gillespie SM; Das J; Wu M; Nocco S; Bonal DM; Nguyen QD; Suva ML; Bernstein BE; Alani R; Golub TR; Cole PA; Filbin MG; Shi Y
Cancer Cell; 2019 Nov; 36(5):528-544.e10. PubMed ID: 31631026
[TBL] [Abstract][Full Text] [Related]
6. H3K27M induces defective chromatin spread of PRC2-mediated repressive H3K27me2/me3 and is essential for glioma tumorigenesis.
Harutyunyan AS; Krug B; Chen H; Papillon-Cavanagh S; Zeinieh M; De Jay N; Deshmukh S; Chen CCL; Belle J; Mikael LG; Marchione DM; Li R; Nikbakht H; Hu B; Cagnone G; Cheung WA; Mohammadnia A; Bechet D; Faury D; McConechy MK; Pathania M; Jain SU; Ellezam B; Weil AG; Montpetit A; Salomoni P; Pastinen T; Lu C; Lewis PW; Garcia BA; Kleinman CL; Jabado N; Majewski J
Nat Commun; 2019 Mar; 10(1):1262. PubMed ID: 30890717
[TBL] [Abstract][Full Text] [Related]
7. Mutations in chromatin machinery and pediatric high-grade glioma.
Lulla RR; Saratsis AM; Hashizume R
Sci Adv; 2016 Mar; 2(3):e1501354. PubMed ID: 27034984
[TBL] [Abstract][Full Text] [Related]
8. Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State.
Nagaraja S; Quezada MA; Gillespie SM; Arzt M; Lennon JJ; Woo PJ; Hovestadt V; Kambhampati M; Filbin MG; Suva ML; Nazarian J; Monje M
Mol Cell; 2019 Dec; 76(6):965-980.e12. PubMed ID: 31588023
[TBL] [Abstract][Full Text] [Related]
9. Histone deposition pathways determine the chromatin landscapes of H3.1 and H3.3 K27M oncohistones.
Sarthy JF; Meers MP; Janssens DH; Henikoff JG; Feldman H; Paddison PJ; Lockwood CM; Vitanza NA; Olson JM; Ahmad K; Henikoff S
Elife; 2020 Sep; 9():. PubMed ID: 32902381
[TBL] [Abstract][Full Text] [Related]
10. Deregulation of histone-modifying enzymes and chromatin structure modifiers contributes to glioma development.
Maleszewska M; Kaminska B
Future Oncol; 2015 Sep; 11(18):2587-601. PubMed ID: 26289459
[TBL] [Abstract][Full Text] [Related]
11. Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways.
Pun M; Pratt D; Nano PR; Joshi PK; Jiang L; Englinger B; Rao A; Cieslik M; Chinnaiyan AM; Aldape K; Pfister S; Filbin MG; Bhaduri A; Venneti S
Acta Neuropathol Commun; 2023 Feb; 11(1):25. PubMed ID: 36759899
[TBL] [Abstract][Full Text] [Related]
12. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression.
Chan KM; Fang D; Gan H; Hashizume R; Yu C; Schroeder M; Gupta N; Mueller S; James CD; Jenkins R; Sarkaria J; Zhang Z
Genes Dev; 2013 May; 27(9):985-90. PubMed ID: 23603901
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic-Targeted Treatments for H3K27M-Mutant Midline Gliomas.
Lu VM; Daniels DJ
Adv Exp Med Biol; 2021; 1283():73-84. PubMed ID: 33155139
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic activation of a RAS/MYC axis in H3.3K27M-driven cancer.
Pajovic S; Siddaway R; Bridge T; Sheth J; Rakopoulos P; Kim B; Ryall S; Agnihotri S; Phillips L; Yu M; Li C; Milos S; Patel P; Srikanthan D; Huang A; Hawkins C
Nat Commun; 2020 Dec; 11(1):6216. PubMed ID: 33277484
[TBL] [Abstract][Full Text] [Related]
15. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
[TBL] [Abstract][Full Text] [Related]
16. Base-resolution methylomes of gliomas bearing histone H3.3 mutations reveal a G34 mutant-specific signature shared with bone tumors.
Sangatsuda Y; Miura F; Araki H; Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Arai Y; Yoshida A; Shibata T; Yoshimoto K; Iihara K; Ito T
Sci Rep; 2020 Sep; 10(1):16162. PubMed ID: 32999376
[TBL] [Abstract][Full Text] [Related]
17. H3-K27M-mutant nucleosomes interact with MLL1 to shape the glioma epigenetic landscape.
Furth N; Algranati D; Dassa B; Beresh O; Fedyuk V; Morris N; Kasper LH; Jones D; Monje M; Baker SJ; Shema E
Cell Rep; 2022 May; 39(7):110836. PubMed ID: 35584667
[TBL] [Abstract][Full Text] [Related]
18. Super Elongation Complex as a Targetable Dependency in Diffuse Midline Glioma.
Dahl NA; Danis E; Balakrishnan I; Wang D; Pierce A; Walker FM; Gilani A; Serkova NJ; Madhavan K; Fosmire S; Green AL; Foreman NK; Venkataraman S; Vibhakar R
Cell Rep; 2020 Apr; 31(1):107485. PubMed ID: 32268092
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells.
Wiese M; Hamdan FH; Kubiak K; Diederichs C; Gielen GH; Nussbaumer G; Carcaboso AM; Hulleman E; Johnsen SA; Kramm CM
Cell Death Dis; 2020 Aug; 11(8):673. PubMed ID: 32826850
[TBL] [Abstract][Full Text] [Related]
20. Histone H3.3K27M Mobilizes Multiple Cancer/Testis (CT) Antigens in Pediatric Glioma.
Deng H; Zeng J; Zhang T; Gong L; Zhang H; Cheung E; Jones C; Li G
Mol Cancer Res; 2018 Apr; 16(4):623-633. PubMed ID: 29453317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
